General contact

Head Office
Novartis International AG
CH-4002 Basel
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 - 17:00, GMT+1
(Central European Time)

Investors

Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel
Switzerland

+41 61 324 79 44

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

pane 4 content

Sandoz (Generics)

Delivering affordable, high-quality medicines

Sandoz, the generic pharmaceuticals division of Novartis, is a global industry leader, offering affordable, high-quality medicines to everyone, everywhere. It is the second-largest division of Novartis.

2010 net sales - USD 8.5 billion

Description

Sandoz develops and produces approximately 1 000 compounds, as well as active substances and intermediates. Our operations span five continents, and we market products in about 130 countries.

In addition to its retail generics business, Sandoz operates three businesses that focus on anti-infectives, oncology injectables and biopharmaceuticals.

Not all products or indications are available in all countries. Regulatory requirements in various countries limit the product information that we can provide. Please consult your healthcare professional about any medical condition or product.

Key marketed products (retail generics):

Product Originator* Drug Description
Omeprazole Prilosec®
(Procter & Gamble)
Ulcer and heartburn treatment
Amoxicillin / clavulanic acid Augmentin®
(GlaxoSmithKline)
Anti-infective
Fentanyl Duragesic®
(Ortho-McNeil-Janssen Pharmaceuticals)
Analgesic
Amlodipine / Benazepril Lotrel Antihypertensive
Simvastatin Zocor®
(Merck & Co)
Cholesterol-lowering treatment
Acetylsteine Fluimucil® Respiratory system
Tacrolimus Prograf®
(Astellas)

Transplantation

Enoxaparin sodium injection Lovenox® Anti-coagulant
Lansoprazole Prevacid® Proton pump inhibitor
Losartan/Losartan HCT Cozaar®/Hyzaar® Hypertension
  1. *Product names identified by a "®" are trademarks that are not owned by or licensed to the Novartis Group of companies.